Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Clinical practice decisions in endocrine therapy.

Untch M, Thomssen C.

Cancer Invest. 2010;28 Suppl 1:4-13. doi: 10.3109/07357907.2010.501637. Review.

PMID:
20653403
2.
3.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456
4.

Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.

Spicer J, Ellis P.

Cancer Lett. 2007 Apr 18;248(2):165-74. Epub 2006 Aug 21. Review.

PMID:
16919870
5.

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.

PMID:
16621229
6.

Are aromatase inhibitors superior to antiestrogens?

Howell A, Buzdar A.

J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):237-47. Review.

PMID:
15860266
7.

Emerging role of aromatase inhibitors in the adjuvant setting.

Goss PE.

Am J Clin Oncol. 2003 Aug;26(4):S27-33. Review.

PMID:
12902874
8.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.

Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.

PMID:
16870082
9.

Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.

Carlson RW, Henderson IC.

Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. Review.

PMID:
14535531
10.
11.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
12.
13.
15.

Extended adjuvant endocrine therapy of early breast cancer.

Chowdhury S, Ellis P.

Curr Med Res Opin. 2005 Dec;21(12):1985-95. Review.

PMID:
16368050
16.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
17.

The use of aromatase inhibitors in adjuvant therapy for early breast cancer.

Jonat W, Hilpert F, Maass N.

Cancer Chemother Pharmacol. 2005 Nov;56 Suppl 1:32-8. Review.

PMID:
16273366
18.

Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.

Fentiman IS.

Int J Clin Pract. 2006 Jun;60(6):689-93. Review.

PMID:
16805754
19.

Endocrine therapy for early breast cancer.

Hussain SA, Williams S, Stevens A, Rea DW.

Expert Rev Anticancer Ther. 2004 Oct;4(5):877-88. Review.

PMID:
15485321
20.

Supplemental Content

Support Center